Betovumeline
CAS 1314018-44-4
MF C8H11N3O MW 165.19 g/mol
(1R,5R)-1-(3-Methyl-1,2,4-oxadiazol-5-yl)-3-azabicyclo[3.1.0]hexane
(1R,5R)-1-(3-methyl-1,2,4-oxadiazol-5-yl)-3-azabicyclo[3.1.0]hexane
muscarinic receptor agonist, ML 007, MPL 0527, 5UXW4B47R9
Betovumeline (also known as ML-007 or MPL-0527) is a muscarinic receptor agonist currently being developed for the treatment of neurological and neuropsychiatric disorders.
It is specifically designed to target muscarinic receptors in the brain, which play a critical role in cognitive and motor functions.
Key Characteristics
- Mechanism of Action: It acts as an agonist for muscarinic acetylcholine receptors (mAChR).
- Research Focus: It is primarily being investigated for its potential in treating neurological disorders, such as schizophrenia or Alzheimer’s disease-related cognitive impairment.
- Chemical Detail: Its chemical structure is (1R,5R)-1-(3-methyl-1,2,4-oxadiazol-5-yl)-3-azabicyclohexane.
- Development Stage: It is an investigational drug, meaning it is currently for research use only and has not yet been approved for general medical or human use.
SYN
https://patentscope.wipo.int/search/en/detail.jsf?docId=US91610057&_cid=P10-MNTPFH-07999-1
SYN
https://patentscope.wipo.int/search/en/detail.jsf?docId=US447604714&_cid=P10-MNTPFH-07999-1
“Compound 1” refers to 1-(3-methyl-[1,2,4]oxadiazol-5-yl)-(1R,5R)-3-aza-bicyclo[3.1.0]hexane having the following structural formula:
AS ON FEB2026 4.574 LAKHS VIEWS ON BLOG WORLDREACH AVAILABLEFOR YOUR ADVERTISEMENT
join me on Linkedin
Anthony Melvin Crasto Ph.D – India | LinkedIn
join me on Researchgate
RESEARCHGATE
join me on Facebook
Anthony Melvin Crasto Dr. | Facebook
join me on twitter
Anthony Melvin Crasto Dr. | twitter
+919321316780 call whatsaapp
EMAIL. amcrasto@gmail.com
References
- Cognition Enhancing Compounds and Compositions, Methods of Making, and Methods of TreatingPublication Number: US-2016199356-A1Priority Date: 2010-09-08
- Cognition enhancing compounds and compositions, methods of making, and methods of treatingPublication Number: US-9403806-B1Priority Date: 2010-09-08Grant Date: 2016-08-02
- Cognition enhancing compounds and compositions, methods of making, and methods of treatingPublication Number: US-9738633-B2Priority Date: 2010-09-08Grant Date: 2017-08-22
- Cognition enhancing compounds and compositions, methods of making, and methods of treatingPublication Number: US-9174972-B2Priority Date: 2010-09-08Grant Date: 2015-11-03
- Methods of treating neurological disordersPublication Number: US-2025032460-A1Priority Date: 2021-11-24
- Methods of treating neurological disordersPublication Number: CN-118510500-APriority Date: 2021-11-24
- Cognition Enhancing Compounds and Compositions, Methods of Making, and Methods of TreatingPublication Number: US-2013274299-A1Priority Date: 2010-09-08
- Cognition Enhancing Compounds and Compositions, Methods of Making, and Methods of TreatingPublication Number: US-2018099956-A1Priority Date: 2010-09-08
- Cognition Enhancing Compounds and Compositions, Methods of Making, and Methods of TreatingPublication Number: US-2016340348-A1Priority Date: 2010-09-08
////////betovumeline, muscarinic receptor agonist, ML 007, MPL 0527, 5UXW4B47R9